Cargando…

The Role of Tumor Protein 53 Mutations in Common Human Cancers and Targeting the Murine Double Minute 2–P53 Interaction for Cancer Therapy

The gene TP53 (also known as protein 53 or tumor protein 53), encoding transcription factor P53, is mutated or deleted in half of human cancers, demonstrating the crucial role of P53 in tumor suppression. There are reports of nearly 250 independent germ line TP53 mutations in over 100 publications....

Descripción completa

Detalles Bibliográficos
Autores principales: Hamzehloie, Tayebeh, Mojarrad, Majid, Hasanzadeh_Nazarabadi, Mohammad, Shekouhi, Sahar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shiraz University of Medical Sciences 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3470295/
https://www.ncbi.nlm.nih.gov/pubmed/23115424
_version_ 1782246241575370752
author Hamzehloie, Tayebeh
Mojarrad, Majid
Hasanzadeh_Nazarabadi, Mohammad
Shekouhi, Sahar
author_facet Hamzehloie, Tayebeh
Mojarrad, Majid
Hasanzadeh_Nazarabadi, Mohammad
Shekouhi, Sahar
author_sort Hamzehloie, Tayebeh
collection PubMed
description The gene TP53 (also known as protein 53 or tumor protein 53), encoding transcription factor P53, is mutated or deleted in half of human cancers, demonstrating the crucial role of P53 in tumor suppression. There are reports of nearly 250 independent germ line TP53 mutations in over 100 publications. The P53 protein has the structure of a transcription factor and, is made up of several domains. The main function of P53 is to organize cell defense against cancerous transformation. P53 is a potent transcription factor that is activated in response to diverse stresses, leading to the induction of cell cycle arrest, apoptosis or senescence. The P53 tumor suppressor is negatively regulated in cells by the murine double minute 2 (MDM2) protein. Murine double minute 2 favors its nuclear export, and stimulates its degradation. Inhibitors of the P53-MDM2 interaction might be attractive new anticancer agents that could be used to activate wild-type P53 in tumors. Down regulation of MDM2 using an small interfering RNA (siRNA) approach has recently provided evidence for a new role of MDM2 in the P53 response, by modulating the inhibition of the cyclindependent kinase 2 (cdk2) by P21/WAF1 (also known as cyclin-dependent kinase inhibitor 1 or CDK-interacting protein 1).
format Online
Article
Text
id pubmed-3470295
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Shiraz University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-34702952012-10-31 The Role of Tumor Protein 53 Mutations in Common Human Cancers and Targeting the Murine Double Minute 2–P53 Interaction for Cancer Therapy Hamzehloie, Tayebeh Mojarrad, Majid Hasanzadeh_Nazarabadi, Mohammad Shekouhi, Sahar Iran J Med Sci Review Article The gene TP53 (also known as protein 53 or tumor protein 53), encoding transcription factor P53, is mutated or deleted in half of human cancers, demonstrating the crucial role of P53 in tumor suppression. There are reports of nearly 250 independent germ line TP53 mutations in over 100 publications. The P53 protein has the structure of a transcription factor and, is made up of several domains. The main function of P53 is to organize cell defense against cancerous transformation. P53 is a potent transcription factor that is activated in response to diverse stresses, leading to the induction of cell cycle arrest, apoptosis or senescence. The P53 tumor suppressor is negatively regulated in cells by the murine double minute 2 (MDM2) protein. Murine double minute 2 favors its nuclear export, and stimulates its degradation. Inhibitors of the P53-MDM2 interaction might be attractive new anticancer agents that could be used to activate wild-type P53 in tumors. Down regulation of MDM2 using an small interfering RNA (siRNA) approach has recently provided evidence for a new role of MDM2 in the P53 response, by modulating the inhibition of the cyclindependent kinase 2 (cdk2) by P21/WAF1 (also known as cyclin-dependent kinase inhibitor 1 or CDK-interacting protein 1). Shiraz University of Medical Sciences 2012-03 /pmc/articles/PMC3470295/ /pubmed/23115424 Text en © 2012: Iranian Journal of Medical Sciences
spellingShingle Review Article
Hamzehloie, Tayebeh
Mojarrad, Majid
Hasanzadeh_Nazarabadi, Mohammad
Shekouhi, Sahar
The Role of Tumor Protein 53 Mutations in Common Human Cancers and Targeting the Murine Double Minute 2–P53 Interaction for Cancer Therapy
title The Role of Tumor Protein 53 Mutations in Common Human Cancers and Targeting the Murine Double Minute 2–P53 Interaction for Cancer Therapy
title_full The Role of Tumor Protein 53 Mutations in Common Human Cancers and Targeting the Murine Double Minute 2–P53 Interaction for Cancer Therapy
title_fullStr The Role of Tumor Protein 53 Mutations in Common Human Cancers and Targeting the Murine Double Minute 2–P53 Interaction for Cancer Therapy
title_full_unstemmed The Role of Tumor Protein 53 Mutations in Common Human Cancers and Targeting the Murine Double Minute 2–P53 Interaction for Cancer Therapy
title_short The Role of Tumor Protein 53 Mutations in Common Human Cancers and Targeting the Murine Double Minute 2–P53 Interaction for Cancer Therapy
title_sort role of tumor protein 53 mutations in common human cancers and targeting the murine double minute 2–p53 interaction for cancer therapy
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3470295/
https://www.ncbi.nlm.nih.gov/pubmed/23115424
work_keys_str_mv AT hamzehloietayebeh theroleoftumorprotein53mutationsincommonhumancancersandtargetingthemurinedoubleminute2p53interactionforcancertherapy
AT mojarradmajid theroleoftumorprotein53mutationsincommonhumancancersandtargetingthemurinedoubleminute2p53interactionforcancertherapy
AT hasanzadehnazarabadimohammad theroleoftumorprotein53mutationsincommonhumancancersandtargetingthemurinedoubleminute2p53interactionforcancertherapy
AT shekouhisahar theroleoftumorprotein53mutationsincommonhumancancersandtargetingthemurinedoubleminute2p53interactionforcancertherapy
AT hamzehloietayebeh roleoftumorprotein53mutationsincommonhumancancersandtargetingthemurinedoubleminute2p53interactionforcancertherapy
AT mojarradmajid roleoftumorprotein53mutationsincommonhumancancersandtargetingthemurinedoubleminute2p53interactionforcancertherapy
AT hasanzadehnazarabadimohammad roleoftumorprotein53mutationsincommonhumancancersandtargetingthemurinedoubleminute2p53interactionforcancertherapy
AT shekouhisahar roleoftumorprotein53mutationsincommonhumancancersandtargetingthemurinedoubleminute2p53interactionforcancertherapy